Developing a new way to measure bone health for osteoporosis treatments
DDT-BMQ-000054: Planning for biomarker qualification, implementation and dissemination for BMD as a surrogate biomarker in future osteoporosis treatment trials: the SABRE project
This study is looking at whether changes in bone density can help us find better and safer treatments for osteoporosis, so that patients can have more effective options to reduce their risk of fractures.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11087988 on NIH RePORTER |
What this research studies
This research focuses on qualifying bone mineral density (BMD) as a reliable measure for evaluating new osteoporosis treatments. By analyzing data from over 150,000 patients in various trials, the project aims to establish a strong link between increases in BMD and reductions in fracture risk. The goal is to facilitate the development of safer and more effective osteoporosis medications, which could lead to more convenient treatment options for patients. The research involves collaboration with the FDA to ensure that BMD can be used as a surrogate endpoint in future clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for osteoporosis or those currently undergoing treatment for the condition.
Not a fit: Patients who are not at risk for osteoporosis or those who have already experienced significant fractures may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new osteoporosis treatments that are safer and more effective, ultimately reducing the risk of fractures for patients.
How similar studies have performed: Previous research has shown promise in using BMD as a surrogate endpoint, indicating that this approach could be a significant advancement in osteoporosis treatment trials.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Black, Dennis M — University of California, San Francisco
- Study coordinator: Black, Dennis M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.